KPRX Key Statistics, Chart & Performance
The current stock price of KPRX is 1.97 USD. In the past month the price increased by 4.23%. In the past year, price decreased by -45.73%.
KPRX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 48.87 | 1.02T | ||
| JNJ | JOHNSON & JOHNSON | 19.94 | 498.60B | ||
| MRK | MERCK & CO. INC. | 11.95 | 261.26B | ||
| PFE | PFIZER INC | 7.78 | 141.57B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 8.22 | 109.81B | ||
| ZTS | ZOETIS INC | 19.85 | 55.45B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.4 | 22.30B | ||
| VTRS | VIATRIS INC | 5.34 | 14.34B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 23.57 | 11.24B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 9.21B | ||
| CORT | CORCEPT THERAPEUTICS INC | 39.55 | 3.66B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.58B |
Related stock screener links
About KPRX
Company Profile
Kiora Pharmaceuticals, Inc. is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. The company is headquartered in Encinitas, California and currently employs 12 full-time employees. The company went IPO on 2015-02-13. The firm is engaged in developing KIO-301, a vision-restoring small molecule that acts as a photoswitch specifically created to restore vision in patients with inherited and age-related degenerative retinal diseases, including retinitis pigmentosa (RP). The company is also developing KIO-104 for the treatment of retinal inflammatory diseases, including Diabetic Macular Edema (DME) and Posterior Non-Infectious Uveitis, a rare T cell-mediated, intraocular inflammatory disease. KIO-104 is a non-steroidal small-molecule inhibitor of dihydroorotate dehydrogenase (DHODH) formulated for intravitreal delivery and is ideally suited to suppressing overactive T-cell activity to treat the underlying inflammation. KIO-101 focuses on treating the ocular manifestation of patients with autoimmune diseases.
Company Info
KIORA PHARMACEUTICALS INC
169 Saxony Rd., Suite 212
Encinitas CALIFORNIA US
CEO: Franz Obermayr
Employees: 12
Phone: 18582249600
KIORA PHARMACEUTICALS INC / KPRX FAQ
What does KIORA PHARMACEUTICALS INC do?
Kiora Pharmaceuticals, Inc. is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. The company is headquartered in Encinitas, California and currently employs 12 full-time employees. The company went IPO on 2015-02-13. The firm is engaged in developing KIO-301, a vision-restoring small molecule that acts as a photoswitch specifically created to restore vision in patients with inherited and age-related degenerative retinal diseases, including retinitis pigmentosa (RP). The company is also developing KIO-104 for the treatment of retinal inflammatory diseases, including Diabetic Macular Edema (DME) and Posterior Non-Infectious Uveitis, a rare T cell-mediated, intraocular inflammatory disease. KIO-104 is a non-steroidal small-molecule inhibitor of dihydroorotate dehydrogenase (DHODH) formulated for intravitreal delivery and is ideally suited to suppressing overactive T-cell activity to treat the underlying inflammation. KIO-101 focuses on treating the ocular manifestation of patients with autoimmune diseases.
What is the current price of KPRX stock?
The current stock price of KPRX is 1.97 USD. The price increased by 1.55% in the last trading session.
Does KIORA PHARMACEUTICALS INC pay dividends?
KPRX does not pay a dividend.
What is the ChartMill rating of KIORA PHARMACEUTICALS INC stock?
KPRX has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Which stock exchange lists KPRX stock?
KPRX stock is listed on the Nasdaq exchange.
How many employees does KIORA PHARMACEUTICALS INC have?
KIORA PHARMACEUTICALS INC (KPRX) currently has 12 employees.
KPRX Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to KPRX. When comparing the yearly performance of all stocks, KPRX is a bad performer in the overall market: 90.22% of all stocks are doing better.
KPRX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to KPRX. KPRX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
KPRX Financial Highlights
Over the last trailing twelve months KPRX reported a non-GAAP Earnings per Share(EPS) of -2.09. The EPS increased by 2.79% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -28.6% | ||
| ROE | -38.12% | ||
| Debt/Equity | 0 |
KPRX Forecast & Estimates
7 analysts have analysed KPRX and the average price target is 12.24 USD. This implies a price increase of 521.32% is expected in the next year compared to the current price of 1.97.
For the next year, analysts expect an EPS growth of -267.71% and a revenue growth -91.05% for KPRX